Ionis Pharmaceuticals' Olezarsen Accepted for FDA Priority Review
Ionis Pharmaceuticals announced that the FDA has accepted for priority review the supplemental new drug application for olezarsen for severe hypertriglyceridemia. The FDA has set a Prescription Drug User Fee Act target action date of June 30.
